Genentech Collaborates with Bicycle Therapeutics to Develop and Commercialize Bicycle-Based Immuno-Oncology Therapies
Shots:
- Bicycle to receive $1.7B including $30M upfront- development & commercialization milestones and royalties on sales of Bicycle based immuno-oncology therapies against multiple targets which will be commercialized by Genentech
- Bicycle will conduct discovery research and early pre-clinical development phase up to candidate selection while Genentech will further develop and commercialize the therapies- post-selection of candidates
- The collaboration leverages Bicycle’s discovery platform and the expertise of both the companies to identify novel therapies for multiple immuno-oncology targets
Click here to read full press release/ article | Ref: Business wire | Image: Genentech
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com